Investors
Titan Medical Inc. is a publicly-held medical device company headquartered in Toronto, Ontario, with shares listed on the Toronto Stock Exchange (TMD) and Nasdaq (TMDI). Titan is focused on the design and development of surgical technologies for application in robotic single access surgery. Design and development activities are directed and performed by the company’s wholly owned U.S. subsidiary, Titan Medical USA Inc. based in Chapel Hill, North Carolina. The Enos™ surgical system, by Titan Medical, is being developed to become the new standard of care in robotic single access surgery with dual 3D and 2D high-definition vision systems, multi-articulating instruments, and an ergonomic surgeon workstation. With the Enos system, Titan intends to initially pursue gynecologic surgical indications. The Enos system is designed with the goals of improving clinical performance, ease of use, operating room efficiency and hospital economics. Certain of Titan’s robotic assisted surgical technologies and related intellectual property have been licensed to Medtronic plc, while retaining world-wide rights to commercialize the technologies for use with the Enos system.
Governance
Financial Events
Titan Medical Q3 2020 Highlights
Shown at Annual General Meeting
Titan at LD Micro: The LD 500 Conference
Titan Presents at H.C. Wainwright 22nd Annual Global Investment Conference
Filings
results on SEDAR
EDGAR Filings– Link to search
results on EDGAR
Recent Press Releases
Archived Press Releases
Titan Medical Inc. to Present at the H.C. Wainwright Virtual Conference
Titan Medical Reports Second Quarter 2020 Financial Results
Titan Medical Confirms Receipt of Deficiency Notice From Nasdaq
Titan Medical to Present at the Society of Robotic Surgery 2020 World Robotic Symposium
Titan Medical Issues Shareholder Update Letter
Titan Medical Reports Full Compliance with Nasdaq Listing Criteria
Titan Medical Appoints Phillip L. McStotts, CPA, CGMA to Board of Directors
Titan Medical Announces Settlement of Pending Litigation With Naglreiter Consulting, LLC
Titan Medical Announces US$18.0 Million Registered Direct Offering Priced At-the-Market
Titan Medical Announces Development and License Agreements With Medtronic and Senior Secured Loan
Titan Medical Receives Nasdaq Delisting Notification and Discloses Plans for Appeal
Titan Medical Reports First Quarter 2020 Financial Results
Titan Medical Announces Closing of US$2.0 Million Registered Direct Offering
Titan Medical Reports 2019 Financial Results
Titan Medical Announces Closing of US$1.2 Million Registered Direct Offering
Titan Medical Announces US$1.2 Million Registered Direct Offering
Titan Medical Announces Departure of Director Domenic Serafino
Titan Medical Issues Letter to Shareholders
Titan Medical Receives ISO 13485 Certification, Provides Update on Fourth Quarter Milestones